$DNTH
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
Healthcare
Sector
Biotechnology
Industry
Marino Garcia
CEO
78
Employees
$87.12
Current Price
$1.74B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $51,196.53 | 599 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $51,196.53 | 599 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $51,196.53 | 599 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 12 | $12,484,333.78 | 151,383 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 5 | 23 | $28,816,677.38 | 351,813 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| May 8, 2026 | Soteropoulos Paula Director | Sale | 599 | $85.47 | $51,196.53 | View Details |
| Apr 9, 2026 | Savitz Ryan EVP, CFO & CBO | Sale | 8,224 | $89.84 | $738,844.16 | View Details |
| Mar 31, 2026 | Savitz Ryan EVP, CFO & CBO | Sale | 2,366 | $82.84 | $195,999.44 | View Details |
| Mar 31, 2026 | Savitz Ryan EVP, CFO & CBO | Sale | 21,825 | $78.86 | $1,721,119.50 | View Details |
| Mar 31, 2026 | Savitz Ryan EVP, CFO & CBO | Sale | 7,232 | $85.54 | $618,625.28 | View Details |
| Mar 31, 2026 | Savitz Ryan EVP, CFO & CBO | Sale | 800 | $81.36 | $65,088.00 | View Details |
| Mar 31, 2026 | Savitz Ryan EVP, CFO & CBO | Sale | 1,390 | $78.33 | $108,878.70 | View Details |
| Mar 31, 2026 | Savitz Ryan EVP, CFO & CBO | Sale | 19,469 | $84.57 | $1,646,493.33 | View Details |
| Mar 31, 2026 | Savitz Ryan EVP, CFO & CBO | Sale | 59,800 | $83.90 | $5,017,220.00 | View Details |
| Mar 31, 2026 | Savitz Ryan EVP, CFO & CBO | Sale | 1,485 | $80.25 | $119,171.25 | View Details |
| Mar 31, 2026 | Soteropoulos Paula Director | Sale | 599 | $80.11 | $47,985.89 | View Details |
| Mar 24, 2026 | Soteropoulos Paula Director | Sale | 27,594 | $78.05 | $2,153,711.70 | View Details |
| Mar 12, 2026 | Garcia Marino Director | Sale | 43,505 | $80.69 | $3,510,418.45 | View Details |
| Mar 12, 2026 | Garcia Marino Director | Sale | 900 | $85.53 | $76,977.00 | View Details |
| Mar 12, 2026 | Garcia Marino Director | Sale | 200 | $83.38 | $16,676.00 | View Details |
| Mar 12, 2026 | Garcia Marino Director | Sale | 12,796 | $82.60 | $1,056,949.60 | View Details |
| Mar 12, 2026 | Garcia Marino Director | Sale | 65,517 | $81.74 | $5,355,359.58 | View Details |
| Mar 12, 2026 | CARR EDWARD CHIEF ACCOUNTING OFFICER | Sale | 15,852 | $80.71 | $1,279,414.92 | View Details |
| Mar 12, 2026 | CARR EDWARD CHIEF ACCOUNTING OFFICER | Sale | 300 | $85.53 | $25,659.00 | View Details |
| Mar 12, 2026 | CARR EDWARD CHIEF ACCOUNTING OFFICER | Sale | 200 | $83.38 | $16,676.00 | View Details |
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
Estimated-$0.97
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated-$1.01
Actual-$1.43
Miss
Revenue
Estimated$242.22K
Actual$284.00K
Beat